Search research articles
Contact Us
Filters
Showing results (31-40 of 40) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 40 results.
Science Advances
|
August 16, 2024
Epinephrine promotes breast cancer metastasis through a ubiquitin-specific peptidase 22-mediated lipolysis circuit
Yuanzhang Zhou, Peng Chu, Ya Wang, et al.
Cancer Discovery
|
October 12, 2019
Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
Remi Klotz, Amal Thomas, Teng Teng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, et al.
JAMA Ophthalmology
|
December 4, 2025
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting
Neel D Pasricha, Stella K Kim, Asim V Farooq, et al.
JAMA Surgery
|
September 7, 2022
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial
Marie Osdoit, Christina Yau, W Fraser Symmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
A Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Cancer Discovery
|
December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Lillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery
Kathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
JAMA Oncology
|
July 24, 2020
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial
, Douglas Yee, Angela M DeMichele, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 40) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 40 results.
Science Advances
|
August 16, 2024
Epinephrine promotes breast cancer metastasis through a ubiquitin-specific peptidase 22-mediated lipolysis circuit
Yuanzhang Zhou, Peng Chu, Ya Wang, et al.
Cancer Discovery
|
October 12, 2019
Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers
Remi Klotz, Amal Thomas, Teng Teng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven, et al.
JAMA Ophthalmology
|
December 4, 2025
Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting
Neel D Pasricha, Stella K Kim, Asim V Farooq, et al.
JAMA Surgery
|
September 7, 2022
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial
Marie Osdoit, Christina Yau, W Fraser Symmans, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2020
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial
A Jo Chien, Debasish Tripathy, Kathy S Albain, et al.
Cancer Discovery
|
December 7, 2019
Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer
Lillian M Smyth, Sarina A Piha-Paul, Helen H Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2023
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery
Kathy S Albain, Christina Yau, Emanuel F Petricoin, et al.
JAMA Oncology
|
July 24, 2020
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial
, Douglas Yee, Angela M DeMichele, et al.
Page
of 4